Abstract:Background: Stroke is a condition of the brain with the highest rates of disability and mortality, and urgently needs more effective treatment options. Edaravone dexborneol is a novel neuroprotective agent compared with Edaravone alone, and it was safe and well-tolerated in treating patients with acute ischemic stroke (AIS). Some studies showed that Edaravone reduced the expression of CXC chemokine 13 (CXCL13) after brain injury. However, the manner in which Edaravone dexborneol played an anti-neuroinflammatory role via regulation of CXCL13 and its downstream signaling pathway has not been elucidated.Methods: Sixty neonatal Sprague-Dawley rats and one hundred and fourty-eight Sprague-Dawley adult rats were used. The experiment was divided into two parts: in vivo and in vitro. Firstly, primary microglia underwent hypoxia-glucose deprivation and reoxygenation (OGD/R) to verify the neuroprotective effect of Edaravone dexborneol on regulating polarization and injury of microglia. Flow cytometry, western blot, immunofluorescence staining, as well as LDH and CCK8 assays were performed. Subsequently, the animal model of AIS was induced via middle cerebral artery occlusion (MCAO). Edaravone dexborneol was administered by tail vein injection at 1 h after MCAO induction. To elucidate the signaling pathway involved in the effect of Edaravone dexborneol on neuroinflammation, recombinant human CXCL13 was administered intracerebroventricularly at 1 h before MCAO. Cerebral infarct area, brain water content, short-term and long-term neurobehavioral tests, western blot, immunofluorescence staining, and Fluoro-Jade C staining were performed.Results: Edaravone dexborneol downgraded the apoptosis and trauma of OGD/R-induced microglia, improved cell viability, modulated microglia M1/M2 polarization, alleviated expression of proinflammatory factors (IL-1β and TNF-α), and promoted the expression of anti-inflammatory factor (IL-4). The in vivo experiment revealed that the expressions of endogenous CXCL13, CXCR5, and p-NF-κB were gradually increased after MCAO, and peaked at 24 h. Edaravone dexborneol significantly improved the short-term neurological deficits at 24 h after MCAO, which was accompanied by alleviating cerebral infarct area, brain edema, and CXCR5 expression on microglia. Edaravone dexborneol also ameliorated long-term neurological deficits at 28 d after MCAO and suppressed the degeneration of hippocampal neurons. Meanwhile, Edaravone dexborneol significantly decreased the expressions of CXCL13, CXCR5, p-NF-κB, IL-1β, and TNF-α, as well as the activation of neutrophil infiltration. Recombinant human CXCL13 abolished these neuroprotective effects of Edaravone dexborneol after MCAO.Conclusions: Our results demonstrate that Edaravone dexborneol regulated the polarization of microglia, attenuated neuroinflammation, and ameliorated neurological deficits in OGD/R-induced microglia and MCAO animal models, possibly by inhibiting CXCL13/CXCR5/NF-κB signaling pathway. These results may help develop new clinical strategies for AIS treatment.

Edaravone dexborneol attenuates cognitive impairment in a rat model of vascular dementia by inhibiting hippocampal oxidative stress and inflammatory responses and modulating the NMDA receptor signaling pathway

Edaravone Dexborneol Alleviates Neuroinflammation by Reducing Neuroglial Cell Proliferation and Suppresses Neuronal Apoptosis/Autophagy in Vascular Dementia Rats

Neuroprotective effect of edaravone on focal cerebral ischemia in rats

Edaravone dexborneol ameliorates cognitive impairment by regulating the NF-κB pathway through AHR and promoting microglial polarization towards the M2 phenotype in mice with bilateral carotid artery stenosis (BCAS)

Edaravone Dexborneol ameliorates the cognitive deficits of APP/PS1 mice by inhibiting TLR4/MAPK signaling pathway via upregulating TREM2

Edaravone attenuates H2O2 or glutamate-induced toxicity in hippocampal neurons and improves AlCl3/D-galactose induced cognitive impairment in mice

Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO‐1 signaling pathway in mice

Effect of Low-Dose Levamlodipine Besylate in the Treatment of Vascular Dementia

Edaravone dexborneol attenuates oxidative stress in experimental subarachnoid hemorrhage via Keap1/Nrf2 signaling pathway

Edaravone Dexborneol Alleviates Cerebral Ischemic Injury via MKP-1-Mediated Inhibition of MAPKs and Activation of Nrf2

Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage

Modified Erchen decoction ameliorates cognitive dysfunction in vascular dementia rats via inhibiting JAK2/STAT3 and JNK/BAX signaling pathways

Edaravone Dexborneol provides neuroprotective effect by inhibiting neurotoxic activation of astrocytes through inhibiting NF-κB signaling in cortical ischemia

Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

Edaravone Dexborneol Attenuates Neuroinflammation by Regulating CXCL13/CXCR5/NF-κB Pathway in MCAO Rats

Preclinical validation of a novel oral Edaravone formulation for treatment of frontotemporal dementia

Sodium Dichloroacetate Stimulates Angiogenesis by Improving Endothelial Precursor Cell Function in an AKT/GSK-3β/Nrf2 Dependent Pathway in Vascular Dementia Rats

Edaravone dexborneol alleviates ischemic injury and neuroinflammation by modulating microglial and astrocyte polarization while inhibiting leukocyte infiltration

Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model

Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke

A Comparative Study of the Neuroprotective Effects of Dl-3-n-butylphthalide and Edaravone Dexborneol on Cerebral Ischemic Stroke Rats